Soluble antigen arrays improve the efficacy and safety of peptide-based tolerogenic immunotherapy

Abstract

ABSTRACTAutoantigen-specific immunotherapy using peptides offers a more targeted approach to treat autoimmune diseases, but the limitedin vivostability and uptake of peptides impedes clinical implementation. We previously showed that multivalent delivery of peptides as soluble antigen arrays (SAgAs) efficiently protects against spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse model. Here, we compared the efficacy, safety, and mechanisms of action of SAgAs versus free peptides. SAgAs, but not their corresponding free peptides at equivalent doses, efficiently prevented the development of diabetes. SAgAs increased the frequency of regulatory T cells among peptide-specific T cells or induce their anergy/exhaustion or deletion, depending on the type of SAgA (hydrolysable (hSAgA) and non-hydrolysable ‘click’ SAgA (cSAgA)) and duration of treatment, whereas their corresponding free peptides induced a more effector phenotype following delayed clonal expansion. Moreover, the N-terminal modification of peptides with aminooxy or alkyne linkers, which was needed for grafting onto hyaluronic acid to make hSAgA or cSAgA variants, respectively, influenced their stimulatory potency and safety, with alkyne-functionalized peptides being more potent and less anaphylactogenic than aminooxy-functionalized peptides. Both SAgA variants significantly delayed anaphylaxis compared to their respective free peptides. The anaphylaxis, which occurred in NOD mice but not in C57BL/6 mice, was dose-dependent but did not correlate with the production of IgG1 or IgE against the peptides. We provide evidence that SAgAs significantly improve the efficacy and safety of peptide-based immunotherapy.SIGNIFICANCE STATEMENTPeptide-based immunotherapy has several advantages over using full antigen as they are easy to synthetize, chemically modify and customize for precision medicine. However, their use in the clinic has been limited by issues of membrane impermeability, poor stability and potencyin vivo, and in some cases, hypersensitivity reactions. Here, we provide evidence that soluble antigen arrays and alkyne-functionalization of peptides could be used as strategies to improve the safety and efficacy of peptide-based immunotherapy for autoimmune diseases by influencing the nature and dynamics of immune responses induced by the peptides.